Resources from the same session
LBA40 - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
Presenter: Nicoletta Colombo
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA40
Presenter: David SP Tan
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Webcast
LBA41 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial
Presenter: Shannon Westin
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA42 - Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
Presenter: Florence Joly Lobbedez
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA41 and LBA42
Presenter: Domenica Lorusso
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Slides
Webcast